Maxim Group Begins Coverage on OS Therapies (NYSE:OSTX)

Analysts at Maxim Group began coverage on shares of OS Therapies (NYSE:OSTX) in a note issued to investors on Tuesday,Benzinga reports. The firm set a “buy” rating and a $8.00 price target on the stock. Maxim Group’s target price indicates a potential upside of 288.35% from the company’s current price.

A number of other research analysts have also weighed in on the stock. EF Hutton Acquisition Co. I raised shares of OS Therapies to a “strong-buy” rating in a research note on Tuesday, September 3rd. Brookline Capital Management raised shares of OS Therapies to a “strong-buy” rating in a research note on Thursday, August 22nd.

OS Therapies Stock Up 3.0 %

Shares of NYSE OSTX opened at $2.06 on Tuesday. The firm’s 50 day moving average price is $2.78. OS Therapies has a 52-week low of $1.58 and a 52-week high of $4.90.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in OS Therapies stock. Virtu Financial LLC purchased a new position in shares of OS Therapies Inc (NYSE:OSTX) during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 10,045 shares of the company’s stock, valued at approximately $28,000.

OS Therapies Company Profile

OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. Its pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers.